<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03428529</url>
  </required_header>
  <id_info>
    <org_study_id>CEP INCA 83/10</org_study_id>
    <nct_id>NCT03428529</nct_id>
  </id_info>
  <brief_title>Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer.</brief_title>
  <acronym>INCAGI004</acronym>
  <official_title>Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancer, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancer, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized two-arm study comparing preoperative CRT using oral capecitabine versus bolus
      5-FU/LV concomitant to external beam radiation (50.5 Gy/28 fractions) for locally advanced
      rectal cancer. Main outcome was clinical response assessed using MRI and endorectal US 6-8
      weeks after CRT. Secondary endpoints were pathological response, adverse effects, sphyncter
      preservation, quality of life, OS and DFS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients harbouring rectal adenocarcinoma T3-4 or N&gt;0 M0 within 10 cm to anal verge were
      randomized in two treatment arms: (1) capecitabina orally 825mg/m2 bid. 5 days a week for 5
      weeks and (2) bolus intravenous 5-FU/LV 350mg/m2/20 mg/m2 D1-D5 on the first and fifth weeks,
      both combined to pelvic radiotherapy, total dose 50.4 Gy in 28 fractions. Clinical stage
      before and after CRT was determined using pelvic Magnetic Resonance Imaging (MRI), endorectal
      ultrasonography (ERUS) and chest, abdominal and pelvic Computer Tomography. Surgery was
      planned 6 to 8 weeks after CRT. Sphincter preservation was always considered when negative
      margins were possible. Pathological assessment included stage (TNM 7th Ed.) and Mandard's
      Tumor Regression Grade (TRG). QOL questionnaires QLQ-C30 and CR38 were completed by patients
      before and after CRT, after surgery and during follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2011</start_date>
  <completion_date type="Actual">December 13, 2016</completion_date>
  <primary_completion_date type="Actual">October 13, 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical downstaging</measure>
    <time_frame>6-8 weeks after CRT</time_frame>
    <description>Clinical downstaging after neoadjuvant treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological downstaging</measure>
    <time_frame>8 weeks after CRT</time_frame>
    <description>Patholgical downstaging after neoadjuvant treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Rectal Neoplasm Malignant</condition>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant capecitabine plus RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-Flourouracil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant 5-Fluorouracil plus RT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine Oral Product</intervention_name>
    <description>Neoadjuvant Capecitabine concomitant to external beam radiotherapy</description>
    <arm_group_label>Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5Fluorouracil</intervention_name>
    <description>Neoadjuvant bolus 5-Fluorouracil concomitante to external beam radiotherapy</description>
    <arm_group_label>5-Flourouracil</arm_group_label>
    <other_name>5-Fu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with histologically proven locally advanced rectal cancer (cT3-4 or positive
        regional lymph node) on endorectal ultrasonography (EUS) or pelvic Magnetic Resonance
        Imaging (MRI) were qualified for this study. Distance from anal verge (AV) should not
        exceed 10 cm measured with rigid proctoscopy. Thorax and abdominal computer tomography (CT)
        exams were taken to rule out distant metastasis. Performance Status ECOG 0-1.

        Exclusion Criteria:

        Previous treatment for rectal cancer (RT, chemotherapy or surgical resection). Previous
        diagnosis of other cancers except nonmelanoma skin cancer. Uncontrolled comorbities
        including heart failure and miocardial infarction in the previous 6 months. Hepatic
        insufficiency and renal failure. Pregnancy. Serious neurologic or psyquiatric disturbances
        that could affect comprehension of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Saif MW, Hashmi S, Zelterman D, Almhanna K, Kim R. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis. 2008 Feb;23(2):139-45. Epub 2007 Oct 2. Review.</citation>
    <PMID>17909820</PMID>
  </reference>
  <reference>
    <citation>Wolff HA, Conradi LC, Beissbarth T, Leha A, Hohenberger W, Merkel S, Fietkau R, Raab HR, Tschmelitsch J, Hess CF, Becker H, Wittekind C, Sauer R, Rödel C, Liersch T; German Rectal Cancer Study Group. Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: long-term results of the German CAO/ARO/AIO-94 phase III trial. Radiother Oncol. 2013 Jul;108(1):48-54. doi: 10.1016/j.radonc.2013.05.009. Epub 2013 Jun 11.</citation>
    <PMID>23768685</PMID>
  </reference>
  <reference>
    <citation>Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999 Oct;5(10):2948-53.</citation>
    <PMID>10537364</PMID>
  </reference>
  <reference>
    <citation>Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45(4):291-7.</citation>
    <PMID>10755317</PMID>
  </reference>
  <reference>
    <citation>Suárez J, Vera R, Balén E, Gómez M, Arias F, Lera JM, Herrera J, Zazpe C. Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis. 2008 Jul;10(6):563-8. Epub 2007 Dec 7.</citation>
    <PMID>18070184</PMID>
  </reference>
  <reference>
    <citation>Tulchinsky H, Shmueli E, Figer A, Klausner JM, Rabau M. An interval &gt;7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol. 2008 Oct;15(10):2661-7. doi: 10.1245/s10434-008-9892-3. Epub 2008 Apr 4.</citation>
    <PMID>18389322</PMID>
  </reference>
  <reference>
    <citation>Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006 Sep 14;355(11):1114-23. Erratum in: N Engl J Med. 2007 Aug 16;357(7):728.</citation>
    <PMID>16971718</PMID>
  </reference>
  <results_reference>
    <citation>Kim JS, Kim JS, Cho MJ, Yoon WH, Song KS. Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer. J Korean Med Sci. 2006 Feb;21(1):52-7.</citation>
    <PMID>16479065</PMID>
  </results_reference>
  <results_reference>
    <citation>Saif MW. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer. 2005 Jul;5(2):89-100. Review.</citation>
    <PMID>16098249</PMID>
  </results_reference>
  <results_reference>
    <citation>Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004 Oct 21;351(17):1731-40.</citation>
    <PMID>15496622</PMID>
  </results_reference>
  <results_reference>
    <citation>Taylor FG, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, Sebag-Montefiore DJ, Tekkis P, Brown G; MERCURY study group. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg. 2011 Apr;253(4):711-9. doi: 10.1097/SLA.0b013e31820b8d52.</citation>
    <PMID>21475011</PMID>
  </results_reference>
  <results_reference>
    <citation>Tiv M, Puyraveau M, Mineur L, Calais G, Maingon P, Bardet E, Mercier M, Bosset JF. Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial. Cancer Radiother. 2010 Oct;14(6-7):530-4. doi: 10.1016/j.canrad.2010.06.017. Epub 2010 Aug 24.</citation>
    <PMID>20797891</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancer, Brazil</investigator_affiliation>
    <investigator_full_name>Rodrigo Otavio de Castro Araujo</investigator_full_name>
    <investigator_title>Dr. Rodrigo Otavio de Castro Araujo</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD could be shared if requested after IRB approval.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

